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Introduction  
 
Mitochondria are intracellular organelles with possible common origin to bacteria 
(endosymbiotic theory). They are the sites ATP (adenosine triphosphate) production via 
oxidative phosphorylation (OXPHOS) but are also involved in cell-specific functions 
such as steroid- and amino acid synthesis, neurotransmitter metabolism, intracellular 
calcium homeostasis and in the regulation of apoptosis. Mitochondria uniquely contain 
their own double-stranded 16.6 Kb circular genome (mitochondrial DNA, mtDNA) that 
is separate from nuclear DNA but is in a complex interaction with it [nuclear-
mitochondrial intergenomial communication]. MtDNA has only 37 genes; the majority 
of mitochondrial proteins are encoded by nuclear DNA. Thereby, mutations in either the 
mtDNA or the nuclear DNA can result in mitochondrial disorder (MTD).  
Although prevalence estimations vary widely; mitochondrial dysfunction is probably 
the most prevalent metabolic abnormality considering the pivotal role mitochondria 
play in the metabolism. More than 200 genetic causes have been identified as potential 
causes of MTDs. Because of polyplasmy, heteroplasmy, the threshold effect and the 
genetic bottleneck effect, all characteristic of the mtDNA, clinical symptomatology vary 
a lot even within the same family. In cells highly dependent on OXPHOS, low amounts 
of mutant mtDNA cause dysfunction making the brain, heart and skeletal muscle the 
most heavily affected organs.  Neurons critically depend on mitochondrial function for 
their metabolism, to establish membrane excitability and to execute the complex 
processes of neurotransmission and plasticity. Actually, growing pharmacologic, 
genetic, biochemical and morphological evidence support the involvement in 
mitochondria in psychiatric and neurodegenerative disorders. Dysfunction of the central 
nervous system (CNS) can result in the combination of neurologic, psychiatric and 
neuropsychologic symptoms. However, very few studies have so far been carried out 
assessing psychiatric or cognitive symptoms in patients with MTD. 
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Objective 
 
1. As a national tertiary care center, we aimed to comprehensively assess the frequency 
of the most common mitochondrial mutations in a cohort of 882 Hungarian patients. 
 
2. We aimed to carry out the complex clinical evaluation and assessment of psychiatric 
symptoms in a well-defined subcohort of patients with genetically proven primary 
mtDNA mutations as compared to disease controls, harboring the CMT or HNPP type 
PMP22 mutation, living with similar level of disability.  
 
3.  Our goal was to comprehensively assess neuropsychological symptoms in the same 
cohort and compare the results to those of matched healthy controls. 
 
4.  We aimed to raise awareness to mitochondrial disorders in the international medical 
community with case reports. 
 
5. We put emphasis on the continuation of our biobank- and register building activity 
(NEPSYBANK, SCHIZOBANK) 
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Patients and methods 
 
Epidemiological study 
 
A total of 1328 Hungarian patients were tested from the North-East, South-West and 
Central region of Hungary (Szabolcs-Szatmár-Bereg, Borsod- Abaúj-Zemplén, Hajdú-
Bihar, Baranya, Pest counties and Budapest) between January 1999 and December 
2012. A subcohort of 882 [485 female, 397 male; 740 adult and 142 children, mean age 
38.8±19.1 years (female: 38.3±15.3 years, male 33.4±17.2 years) with a range of 1-75 
years] patients were screened for A3243G, A8344G, T8993C, T8993G and mtDNA 
deletions. Patients were referred from county hospitals to the three genetic centers, 
based on the symptomatology and laboratory findings, for further evaluation and 
genetic analysis. All adult patients had a presentation consistent with mitochondrial 
disease i.e. the various combinations of symptoms such as short stature, epilepsy, ataxia, 
myopathy, lipomatosis, ophthalmoplegia externa, hypoacusis, exercise intolerance, 
myalgia, recurrent ischaemic stroke syndrome, cognitive dysfunction, psychiatric or 
endocrine disorder.  In 70% of the investigated cohort, more than 5 organ systems were 
affected. Leading symptoms were myopathy, exercise intolerance, ataxia, PEO and 
psychiatric disorders.  Patients with advanced age and/or any autoimmune disorder were 
excluded from the cohort with deletions because of the frequent occurrence of 
secondary somatic mutations in both case scenarios. In the case of young children, 
mitochondrial disease was suspected on the bases of muscle hypotonia, delayed 
psychomotor development, lactic acidosis and epileptic seizures.  
We have screened 446 patients [217 male, 229 female, 366 adult and 80 children, 
35.82±18.47 (male: 32.58±17.72 years, female: 38.98±18.64) with a range of 7-63 
years] for the three primary LHON mutations (G3460G, G177884G, T14484C), based 
on the suggestive symptomatology. Written, informed consent was obtained from all 
participants. The study was carried out according to the Helsinki Declaration and was 
approved by the Research and Ethics committee of Semmelweis University. 
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Psychiatric and neuropsychologic study  
 
Nineteen patients (Patient 1-19, 13 female, 6 male) with primary mutation of the 
mtDNA were selected for a detailed psychiatric and neuropsychologic assessment.  Of 
the 19 patient, only 13 probands has been included in the statistical analysis in order to 
keep the variables independent. Mean age for the 13 probands, included in the statistical 
analysis was 34±8.43 years (male: 27.25±6.8; female: 36.66±7.65), average years of 
education was 12.84±1.21 years (male: 13.25±1.5; female: 12.66±1.12).  As control for 
the psychiatric assessment, 10 patients (HN patients, Patient 20-29, 4 female, 6 male, 
mean age was: 40±10.99, average years of education was 14.2±3.85 years) with PMP22 
mutation were examined. Diagnosis was based on clinical features supported by the 
presence of the PMP22 gene mutation in HN patients. Thirteen healthy controls 
matched for age, sex and education (9 female, 4 male, mean age: 33.77±9.19, average 
years of education 14±0.9 years) were examined for the neuropsychological 
examination. All participants of the study were Caucasian and visited the clinic within 1 
year. Written, informed consent was obtained from all participants. These studies were 
carried out according to the Helsinki Declaration and were approved by the Research 
and Ethics committee of Semmelweis University. 
 
Methods 
 
Histopathological evaluation was carried out using standard methods. Mitochondrial 
disorder was supported by the presence of ragged blue, ragged red and COX 
(cytochrome oxidase) negative fibers.   
DNA was extracted from blood (in 570 cases) or if the blood sample yielded no result 
but the suspicion of MTD was high, skeletal muscle tissue (in 312 cases) by QIAamp 
DNA Blood or Tissue kit, according to the manufacturer’s (QIAgen, Hilden, Germany) 
instructions. The A3243G, A8344G and T8993C/G mutations were screened based on a 
method described earlier using restriction fragment length polymorphism (RFLP) after 
PCR amplification. The entire mtDNA tRNA was sequenced in 200 cases (120 female, 
mean age: 30.8±11.3, 80 male, mean age: 29.9±13.5) where there was a high suspicion 
of MTD based on myopathology and/or clinical symptomatology but no common 
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mutation was found. The ratio of heteroplasmy was measured by Quantity One 
Software (Bio-Rad Corp. Hertfordshire, UK). The mtDNA deletion was screened for by 
long PCR methods using Phusion DNA Polymerase (Finnzymes). The PMP22 deletion 
and duplication in the HN group was detected with real time PCR as published earlier 
(Aarskog et al, 2000). The 5HTTLPR (serotonin-transporter-linked polymorphic region) 
genotypes of both MTD and HN patients were detected by previously reported method 
(Heils et al, 1996).  
In the case of the 19 selected patients, functional ability was assessed using the 
Hungarian validated version of the Stanford Health Assessment Questionnaire 20-item 
Disability Index (HAQ-DI). Patients’ charts were reviewed for duration of disease, 
medication and brain CT or MRI scans in case of the 19 patients selected for further 
evaluation. Psychiatric assessment used the Symptom Checklist-90-Revised (SCL-90-
R) and the Beck Depression Inventory-Short Form (BDI-SF) self inventories. The 
clinician-administered 21-item Hamilton Depression Rating Scale (HDRS) and the 
clinical version of the Structured Clinical Interview for the DSM-IV axis-I (SCID-I) and 
axis-II disorders (SCID-II) were also used.  
Cognitive functions were evaluated by the Rey Auditory-Verbal Learning Test 
(RAVLT), the Stroop Color (Stroop C) and Color-Word (Stroop CW) tests, the Trail 
Making Tests (TMTA, TMTB), the category (aka semantic) and letter Fluency Tests 
and the Hungarian validated version of the Wechsler Adult Intelligence Scale. 
The frequency of the mutations was calculated from the number of patients with 
pathogenic substitutions divided by the total number of investigated patients. The 95% 
confidence interval (CI) was calculated according to the standard method. 
In the other studies, correlation of total scores in GSI, BDI and HDRS with HAQ-DI in 
both groups was evaluated using Pearson's correlation. Differences between the patient 
and control groups were assessed using Chi-Square test for categorical variables and 
parametrical (t-test) or non-parametrical tests (Wilcoxon Mann-Whitney test) for 
continuous variables (depending on the distribution of the variables). The normality of 
the data was checked by Shapiro-Wilk test (data not shown). All tests were two tailed 
and p values ≤ 0.05 were deemed significant. SCL-90-R was analyzed with SAS System 
for Windows (Release 9.1 TS Level 1 M3, Statistical Analysis System, SAS-Institute 
USA).  
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Results 
 
Epidemiology 
 
We performed the first systematic assessment of the frequencies of the most common 
mtDNA mutations - A3243G, A8344G, T8993C and T8993G tRNA mutations and the 
common mtDNA deletions - in Central-Eastern Europe. The A3243G substitution in the 
tRNA
Leu1(UUR)
 was found in a heteroplasmic form in 11 index patients and further 15 
family members from the investigated 882 patients. The frequency of the A3243G 
mutation was 2.61% (95% CI: 0.0207-0.0315). The heteroplasmic A8344G mutation of 
the mitochondrial tRNA
Lys 
gene was present in 13 patients from 3 families, which is 
1.47% (95% CI: 0.0106-0.0187). 
With sequence analysis of the tRNA, we found 6 further pathogenic mutations in 17 (11 
female, 6 male) patients out of the 200 investigated cases which is 1.93%.These were 
the T3250C, the G4298A, the A7445G, the T7510C and the new, pathogenic A8332G 
mutations. The overall frequency of tRNA mutations was found to be 6.35% (56/882 
cases) in the Hungarian population. 
Of the protein coding mutations, the T8993C and T8993G substitution that were present 
in 4 cases among 882 patients, yielding an overall frequency of 0.45% (95% CI: 
0.00038-0.0086).  
The three primary LHON mutations were detected altogether in 80 cases (41 male, 39 
female) in homoplasmic form. The A3460G mutation was found in 9 cases (6 male, 3 
female). The G11778A mutation was detected in most cases in 66 cases (34 male, 32 
female) and the T14484C was found in 5 cases (2 male, 3 female) from the 446 patients. 
The frequency of the mutations separately: 2.02% of the G3460A (95% CI: 0.0135-
0.0269), 14.80% of the A11778G (95% CI: 0.1312-0.1648) and 1.12% of the T14484C 
(95% CI: 0.0062-0.0162), the summarized frequency of these mutations was 17.94% 
(95% Cl: 0.1612-0.1976). 
Single mtDNA deletions were detected in 132 out of 882 cases representing 14.97% 
(95% CI: 0.1377-0.1617), multiple deletions were present in 53 cases which is 6.01% of 
the investigated cohort (95% CI: 0.0521-0.0681).  
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Psychiatric and neuropsychologic evaluation 
 
Among the 19 patients selected for further evaluation, ten patients had common 
mutation of mtDNA (4 cases of A3243G, 4 cases of A8344G and one of the A8332G 
substitutions). Three patients had protein coding mutation; 2 of them had the T8993G 
and one had the A12770G substitution. Three patient harbored common mtDNA 
deletion and four had different combination of nonsynchronous mtDNA SNPs (single 
nucleotide polymorphism). 
In the HN group, 9 patients harbored a duplication (Charcot-Marie-Tooth phenotype, 
CMT), and 1 had a deletion (Hereditary Neuropathy with Liability to Pressure Palsy 
phenotype, HNPP) in the PMP22 gene. 
In the MTD group, 5 patients harbored the long-long (L/L), 10 patients harbored the 
long/short (L/S) while 4 patient had the short-short (S/S) genotype (Pt 6, 7, 8, 19).  In 
the HN group, 3 patients had the L/L, further 3 patients the L/S, and 4 patients the S/S 
polymorphism (Pt 22, 23, 27, 28). 
The MTD and HN groups did not differ significantly in gender (χ²=1.9652; p=0.1610), 
age (t= -1.42; p=0.1711) or education (t= -1.20; p=0.243). Mean HAQ-DI score was 
0.82 in the MT (range: 0 - 1.625) and 0.71 in the HN group (range: 0 - 1.625) which did 
not differ significantly (p=0.6076) implying comparable level of disability of the two 
groups. Hypoacusis, ataxia, myopathy, neuropathy and exercise intolerance were the 
most common neurological symptoms in the MTD group. HN patients mostly had distal 
type paresis and muscle atrophy. Some patients were taking psychiatric drugs at the 
time of the assessment. Various alterations have been found on neuroimaging studies, 
the most common was cerebral and/or cerebellar atrophy. 
 
The MTD and HN groups’ BDI-SF and HDRS score differed significantly (12.85 vs 
4.40, p<0.031, and 15.62 vs 7.30, p<0.043, respectively). Statistical difference was also 
found in the GSI score (1.44 vs 0.46, p<0.013) and the nine subscales of the SCL-90-R 
scale. Patients harboring the S/S genotype had lower levels of depression than the rest 
of the group (BDI average score of 4.5 vs 11.8, see Table 8). 
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A variety of psychiatric disorders; current diagnosis in 6 (31%), past diagnosis in 8 
(42%), lifetime prevalence in 9 MTD cases (47%) were diagnosed with SCID-I. 
Personality disorder was found in 8 MTD cases representing 42% of the group. 
Int he HN group, depression was more prevalent in the subgroup harboring the S/S 
genotype than the rest of the group (BDI score of 6.75 vs 2.83). In the HN group, 3 
patients (30%) had past and current psychiatric diagnosis. Lifetime prevalence was 20% 
(2 patients) for dysthymia, 10% (1 patient) for major depression, bipolar II, mood 
disorder due to general medical condition and alcohol abuse (Table 11). No personality 
disorder was detected. 
 
On the RAVLT, there positive correlation between the number of words retained and 
the number of trials, which is slightly stronger in the control group (r=0.603, p<0.0001 
for patients vs. r=0.748 p<0.0001 for controls). We detected significantly impaired 
short-term (RAVLT1, mean of patients = 5.46 ± 2.1062, mean of controls = 8.0 ± 1.354, 
p = 0.0015) and delayed recall (RAVLT6, mean of patients: 7.15, mean of controls = 
12.15, p = 0.0001). The number of read words differed significantly on both the Stroop 
C and the Stroop CW (Stroop C_60 Pt: 65.77±27.7, controls: 87.08±8.36, p = 0.018, 
Stroop CW_60 Pt: 42.77±22.9, Controls: 61±11.68, p = 0.021) No difference has been 
found in the number of errors on either test (Stroop C_error Pts: 0.77 ± 1.16, Controls: 
0.75±1.35, p = 0.97, Stroop CW_error Pts: 3±3.96, Controls: 1. 08±1.44, p = 0.127). 
Results on TMT show that patients’ performance is over the cut-off values for 
abnormality (Lezak 2004) (TMTA: 96.39 vs. 86 (1st percentile), TMTB: 186.08 vs. 155 
(10th percentile). Motor function was found to be impaired, although patients could 
perform the task without any mistakes – only in a much slower way (TMTA time Pts: 
96.39 ± 62.5 msec, controls: 34.15 ± 8.1 msec, p = 0.0016). The difference was greater 
when motor and executive functions were assessed simultaneously a in a more complex 
task (TMTB time Pts: 186.08 ± 109.3 msec, controls: 64.39 ± 26.8 msec, p = 0.0007). 
Patients with TMTA time exceding 100 sec performed significantly worse on the WAIS 
Block Design subscale (mean of Pts with a TMTA_time>100 sec: 71.6, mean of Pts 
with TMTA_time<100 sec: 96.25, p = 0.0497).  
In both groups, scores were higher for category than for letter fluency (Pts: 48.77 ± 21.8 
vs 23 ± 11.9 (p = 0.0001), controls 67.77 ± 12 vs 38.8 ± 10.1 (p = 0.0001) showing 
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better performance. Difference of means was not found to be significant between the 
groups showing a similar pattern in both groups.  
General intelligence, assessed with the WAIS, was in a lower zone of the normal range 
for the Pt group (FSIQ Pts:  95.2 ± 22.8, controls: 123.7 ± 8.6, p = 0.0003, patients’ 
mean is 76.9% of the controls’ mean). The difference between the two groups was 
significant for both the VQ and the PQ, although a greater impairment was detected in 
the latter component showing primarily nonverbal impairment (VQ Pts: 97.00 ± 15.7, 
controls: 117.62 ± 9.9, p = 0.0007, patients’ mean is 82.5% of the controls), PQ Pts: 
94.1 ± 28.8, controls: 127.23 ± 8.3, p = 0.0006, patients’ mean is 73.9% of controls).  
Significantly lower score on the WAIS Block Design has been found for those with a 
long TMTA time (greater than 100 sec) (71.6 vs 96.25, p = 0.0497). A significant 
positive correlation was found between age and StroopC_60 score (r = 0.601, p= 0.029), 
as well as between age and TMTA time (r = 0.609, p = 0.027). Negative correlation 
between HAQ-DI FSIQ was also significant (r = -0.594 p = 0.032). Group I. Pts had 
significantly worse performance than all other patients on the RAVLT5 (p = 0.01) and 
sum of letter fluency (p = 0.009). Patients with normal neuroimaging findings had a 
higher mean FSIQ (110 vs 91.33), VQ (103.25 vs 94.22) and PQ (115.75 vs 84.44) than 
the rest of the group, although these were not significant differences (p-values of 0.246, 
0.427, 0.106, respectively). Patients with structural alteration in the cerebellum had 
significantly lower PQ (68 vs 105, p = 0.042) and greater VQ-PQ difference (22 vs 5, p 
= 0.029), than the rest of the group. The VQ and FSIQ scores of the same subcohorts 
did not differ (p = 0.035 and p=0.088, respectively). In case of Patient 16 we had the 
chance to do a repeat exam 6 months apart which showed the progression of symptoms. 
 
Case presentation 
 
In the topic of the frequently observed lack of concern about the disease process in our 
MTD patients, in a previous work, we presented the case of Patient 2, a now 50-year-
old female in detail. Our case presentation looked to answer whether it was the 
physicians’ unawareness to rare disorders and frustration of not being able to synthesize 
the results or the patient’s belle indifference that resulted in a 40 years delay of the 
correct diagnosis. 
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Her symptoms began in childhood and consisted mainly of ataxia, hearing impairment, 
balance problems, terminal ileitis and dysthymia. She spent 40 years in the healthcare 
system with diagnoses such as Fahr syndrome, CADASIL, pseudohypoparathyreosis 
and somatization disorder, the latter significantly reducing her eligibility for incapacity 
benefit. On assessment in our center she an elevated level of resting serum lactate (4 
mmol/l), creatine-kinase (CK, 305 U/l) and lactate dehydrogenase (LDH, 490 U/l) were 
found. A neurological examination depicted bilateral ptosis, dysarthria, diffusely 
hypotrophic muscles, latent paresis of the right arm, distal type of hypoesthesia in all 
limbs, generalized areflexia and marked truncal ataxia. Psychiatric assessment showed 
subclinical depression, neuropsychological assessment measured a balanced but 
subnormal profile. The diagnosis of MELAS syndrome was confirmed by 
myopathological and genetic investigation.  
 
Biobank- and register building activity 
 
NEPSYBANK, a disease-based biobank collecting both phenotypical and 
environmental data and biological materials such as DNA/RNA, whole blood, plasma, 
cerebral spinal fluid, muscle / nerve / skin biopsy, brain, and fibroblast. The target of the 
diseases is presently stroke syndromes, dementias, movement disorders, motoneuron 
diseases and mitochondrial disorders. NEPSYBANK coordinates the biobanking 
activities of the neurological and psychiatry departments of the four medical universities 
in Hungary. Anamnesis, childhood development, family history, medical and 
neurological status, ECG, electrophysiological records, neuroimaging, laboratory data, 
pathological records, respiratory chain activities and medication of patients with MTD 
has been uploaded to the registry.  
Another biobank focusing on the neurodevelopmental disease schizophrenia 
(SCHIZOBANK) has been built between 2009 and 2013. Mitochondrial dysfunction is 
frequent in schizophrenia and thus this biobank has been a valuable source of our 
research. Between 2009 and 2013, detailed clinical data and biological samples of 535 
patients with schizophrenia have been uploaded to SCHIZOBANK 
(www.schizobank.hu) by the participating institutions. 
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Conclusion 
 
1. We carried out the first genetic epidemiologic study systematically investigating the 
frequency of the most common mtDNA mutations - A3243G, A8344G, T8993C and 
T8993G tRNA mutations and the common mtDNA deletions - in Central-Eastern 
Europe.  The mutation frequency in Hungarian patients was similar to other Caucasian 
populations for the hot spot mutations. The marked variability of published prevalence 
data is possibly due to the difference in selectional criteria and the examined tissue 
(blood or muscle), making it difficult to compare results. It is important that similar 
prevalence studies be carried out in different populations in the future in order to 
accurately assess the importance and impact of mitochondrial diseases and to 
adequately manage these patients.  
2. Using a comprehensive clinical assessment, we demonstrated that psychiatric 
symptoms, especially mood disorders are more frequently present in patients with MTD 
compared to HN patients, who live with comparable level of disability. Psychiatric 
symptoms of these patients do not have a classic course, are frequently treatment 
resistant, do not correlate with the severity of the somatic symptoms and thereby might 
be an independent manifestation of the mitochondrial dysfunction. 
3. We elucidated hitherto unknown aspects of cognitive decline in a well-defined cohort of 
patients with MTD. Our results indicate a decreased but balanced intelligence profile 
with a variety of focal cognitive deficits present in these patients. Cognitive decline is 
greater than predicted on clinical grounds or neuroimaging and tend to progress, as 
demonstrated with the case of Patient 16. Mitochondrial disease is a multisystemic 
process in which neurodegeneration seems to be present irrespective of the mutation 
type.  
4. In order to raise awareness to MTDs in the international medical community, we 
reported a case of a woman with multisystemic symptoms where the signs of 
somatoform disorders were present with laboratory abnormalities and a positive family 
history, and emphasized that in similar cases mitochondrial workup is warranted to 
avoid misdiagnosis. 
5. We established the registry and biobank of mitochondrial disorders (NEPSYBANK) 
and schizophrenia (SCHIZOBANK). 
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